What's Happening?
Alida Biosciences has launched the EpiPlex Tri-Mod Service, a groundbreaking tool for simultaneous profiling of three key mRNA modifications: N6-methyladenosine (m6A), inosine, and pseudouridine. This service provides researchers with a comprehensive
view of RNA-level regulation, which is crucial for understanding disease biology. The EpiPlex platform uses proprietary enzyme-driven chemistry to convert RNA modifications into sequencing-readable signals, enabling sensitive and quantitative analysis from RNA-limited clinical samples. This advancement allows for large-scale studies that can power AI-driven models and enhance understanding of cellular processes relevant to human disease. The service is now available to academic and biopharma partners, offering a new window into cell state and disease.
Why It's Important?
The launch of the EpiPlex Tri-Mod Service represents a significant advancement in the field of molecular biology and translational research. By enabling detailed profiling of RNA modifications, researchers can gain insights into cellular processes that are critical for understanding and treating various diseases. This service bridges the gap between molecular biology and clinical outcomes, providing data that complements genomic and transcriptomic analyses. The ability to study RNA modifications in lowly expressed transcripts opens new avenues for research and potential therapeutic interventions. This development is particularly important for the biopharma industry, as it enhances the ability to develop targeted treatments based on a deeper understanding of disease mechanisms.
